MKGAF (Merck KGaA) Other Stockholders Equity: $775 Mil (As of Mar. 2026)


MKGAF Merck KGaA MKGAF
84 GF Score
Price $164.15
GF Value $159.56
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Merck KGaA Other Stockholders Equity?

Merck KGaA MKGAF +1.82% 84 Other Stockholders Equity is $775 Mil as of Mar. 2026. GuruFocus rates MKGAF with a GF Score™ of 84/100 and a GF Value™ of $159.56 (Fairly Valued). The stock has 10 warning signs investors should review.

Merck KGaA's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $775 Mil.

Merck KGaA's quarterly Other Stockholders Equity declined from Sep. 2025 ($421 Mil) to Dec. 2025 ($204 Mil) but then increased from Dec. 2025 ($204 Mil) to Mar. 2026 ($775 Mil).

Merck KGaA's annual Other Stockholders Equity increased from Dec. 2023 ($2,261 Mil) to Dec. 2024 ($3,610 Mil) but then declined from Dec. 2024 ($3,610 Mil) to Dec. 2025 ($204 Mil).

Merck KGaA Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Other Stockholders Equity Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,062.15 3,268.01 2,260.63 3,610.47 203.75

Merck KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,663.78 615.92 421.36 203.75 774.57
MKGAF
84GF Score
Merck KGaA MKGAF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $775 Mil mean?
Merck KGaA (MKGAF) has a Other Stockholders Equity of $775 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Merck KGaA and its competitors.
Is Merck KGaA's Other Stockholders Equity too high?
Merck KGaA's current Other Stockholders Equity is $775 Mil. Overall, Merck KGaA has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Other Stockholders Equity compare to ZTS and UTHR?
Merck KGaA's Other Stockholders Equity of $775 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Merck KGaA and its competitors. Merck KGaA's current Other Stockholders Equity is $775 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Based on GuruFocus' analysis, Merck KGaA (MKGAF) is currently considered Fairly Valued. The stock's GF Value™ is $159.56, compared to a current price of $164.15 — trading 2.9% above its estimated fair value. The current Other Stockholders Equity is $775 Mil. Merck KGaA's overall GF Score™ is 84/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Merck KGaA (MKGAF), the current Other Stockholders Equity is $775 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (MKGAF) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be overvalued. The current stock price of $164.15 is trading 2.9% above its estimated GF Value™ of $159.56. GuruFocus considers Merck KGaA to be Fairly Valued.

Key valuation signals for MKGAF:

  • Other Stockholders Equity: $775 Mil
  • GF Value™: $159.56 vs. price of $164.15 (2.9% above fair value)
  • GF Score™: 84/100 with 10 warning signs

No single metric tells the full story. See the MKGAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
84GF Score

Get the complete analysis for MKGAF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$164.15
Price
$159.56
GF Value